[A therapeutic trial in patients with spasmophilia].
As the clinical manifestations of spasmophilia are characterized by their striking polymorphism, quantitative assessment, which is requisite in order to evaluate therapeutic effectiveness, is a difficult task. The authors have attempted to analyze clinical, electrical and biological data from 30 patients. Each of these patients, given only manganese-cobalt oligosol and magnesium oligosol for two months, in two daily doses, had at least two groups of symptoms. Analysis of results shows that the most significant improvement was clinical: improvement was satisfactory or very satisfactory in 83% of patients tested, with muscular relaxation being recorded first, In relation with these clinical results, is the 59% improvement rate in EMG controls. Improvement in overall laboratory data was conclusive in only 24% of patients; however, if only the changes in intraerythrocytic magnesium, which is the only parameter with real clinical value (60% of abnormal results before treatment) are considered, improvement or return to normal values was recorded in 83% of cases.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003035:Cobalt / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*; D008297:Male; D008345:Manganese / Q000627:therapeutic use*; D008875:Middle Aged; D013746:Tetany / Q000188:drug therapy* / Q000503:physiopathology
D003035:Cobalt; D008345:Manganese; D008274:Magnesium
Essai thérapeutique chez les spasmophiles.